ESPERITE N.V. (ESP) WITH CRYOSAVE CONTRIBUTES TO TREATING A 9 YEAR OLD CHILD WITH THALASSEMIA MAJOR IN SWITZERLAND
(Thomson Reuters ONE) -
CryoSave confirms the importance of cord blood stem cells in regenerative
medicine.
Last week, CryoSave released a cord blood stem cell unit from the state of the
art laboratory in Geneva for the clinical treatment of a young boy who suffers
from thalassemia major. The 9 year old patient will receive an allogeneic
transplant in Switzerland of the cord blood stem cells from his now 2 year old
brother.
Zutphen, The Netherlands - 25 April 2017
Beta thalassemia, is a genetic abnormality of the hemoglobin molecule whereby
patients do not transport oxygen properly in their red blood cells. From around
2 years of age, children typically become chronically anemic, tired and prone to
infection. They fail to grow normally and are, in the severest cases, dependent
on blood transfusions for survival, with the inherent risks and complications
that this may bring.
Hemoglobinopathies are included in the current list of around 70 diseases that
can be treated with stem cells. They are a group of genetic defects that result
in the abnormal structure of one of the globin chains of the hemoglobin molecule
that is responsible for carrying oxygen in the blood. It affects over 200
million people in some form, 4.7 million of them severely, mostly in families of
Greek, Italian middle Eastern and southern Asian or African descent. Stem cell
transplantation offers a chance of a cure by rebooting the hematopoietic system
to produce normal red blood cells contain normal hemoglobin. The best possible
donor in this scenario is a perfectly HLA matched sibling as in this case.
Stem cells are present in the human body throughout life, constantly repairing
tissue damaged by normal activity, environment and other extraneous factors.
Aware of this inherent ability of stem cells to regenerate biological
functionalities, medical researchers believe that stem cells treatments have the
potential to change the face of human suffering by providing treatments for many
currently incurable diseases.
The first umbilical cord blood stem cell transplant has been performed in 1988
and since then more than 36'000 transplants have been completed worldwide. Cord
blood is rich in stem cells that have a high proliferative and differentiation
potential.
Banking cord blood is a way of preserving potentially life-saving cells that
usually get thrown away after birth. Increasing number of families throughout
the world are choosing to store stem cells from the umbilical cord blood and
umbilical cord tissue of their newborn children. The collection procedure poses
no risk to the mother or the newborn and storing these cells makes them
available for potential therapy in the future and therefore a form of insurance
for life. Under private storage, from the moment of collection the stem cells
are the property of the child under the guardianship of the parents. The cells
will be safely stored in case the child or a family member needs them.
CRYOSAVE is the largest European allogenic and autologous private stem cell bank
fully authorized for transplantations by the National Swiss Agency for
therapeutic products and fully accredited as a licensed Organ and Tissue
Establishment.
The state of the art laboratory in Geneva, Switzerland has an ideal location at
the heart of Europe offering regulatory and geopolitical stability. Protected by
advanced regulations, the Geneva Health Valley represents a hub of excellence
and innovation.
CryoSave believes that the Cord Blood and Cord Tissue should be saved, either in
a family bank or made available for public use or research. Thanks to thoughtful
parents
and CryoSave's high quality cryopreservation, numerous Stem Cells samples have
been used to treat patients with Aplastic Anaemia, Congenital immunodeficiency,
Cerebral Palsy, Acute Lymphoblastic Leukaemia, Medulloblastoma.
About ESPERITE
ESPERITE Group (www.esperite.com), listed at Euronext Amsterdam and Paris
(ticker: ESP), established in 2000, is the leading international company in
regenerative and predictive medicine, operational in almost 40 countries with a
network of 6'000 clinics worldwide. ESPERITE serves clients in its state-of-the-
art lab facilities in Switzerland, Belgium, Germany, Dubai, South Africa and
Portugal.
CryoSave (www.cryo-save.com) is Esperite's leading international stem cell
processing and cryo-conservation company and the largest family stem cell bank
in Europe, which offers umbilical cord blood and cord tissue storage to parents.
The family stem cell bank, CryoSave (www.cryo-save.com), stores 300'000 samples
from umbilical cord blood and cord tissue.
Genoma (www.genoma.com) is Esperite's portfolio which comprises innovative tests
based on sequencing and genomics: Tranquility, a non-invasive prenatal test
(NIPT) and proteomics: Verity, a metabolic disorder test and Serenity, a breast
cancer screening test. Esperite is already working on the development of some
other exclusive technologies in collaboration with the market leaders in this
field.
The Cell Factory (www.cell-factory.com) is Esperite's know how R&D division, at
the heart of the value chain, between stem cells collection & storage and the
existing and future treatments in the regenerative medicine. Esperite, mainly
focused on autologous treatments, will play a key role in research for the
development of new medical treatments, in partnership with medical research
center, public universities and private partners.
To learn more about the ESPERITE Group, or to book an interview with CEO Mr.
Frédéric Amar: +31 575 548 998 - ir(at)esperite.com or visit the website at
www.esperite.com.
CRYOSAVE PR TREATMENT:
http://hugin.info/143308/R/2098339/794704.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2017 - 07:17 Uhr
Sprache: Deutsch
News-ID 537967
Anzahl Zeichen: 6953
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ESPERITE N.V. (ESP) WITH CRYOSAVE CONTRIBUTES TO TREATING A 9 YEAR OLD CHILD WITH THALASSEMIA MAJOR IN SWITZERLAND"
steht unter der journalistisch-redaktionellen Verantwortung von
Esperite N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
